Adagio Medical (Nasdaq:ADGM) announced today that it received FDA investigational device exemption (IDE) to expand its FULCRUM-VT trial.
BD (NYSE:BDX) announced today that it received CE mark approval for its Liverty TIPS stent graft system.
Supira Medical announced today that it received FDA approval to initiate a new trial of its percutaneous ventricular assist device (pVAD).
MILFORD, Mass., April 8, 2026 /PRNewswire/ — Waters Corporation (NYSE: WAT) today announced that the U.S. Food and Drug Administration (FDA) has cleared the Onclarity HPV Self-Collection Kit and approved the BD Onclarity HPV Assay with extended genotyping for at-home use, marking a significant milestone in expanding access to cervical cancer screening, and removing barriers that currently prevent many individuals from receiving routine screening.
TriCares announced today that it received FDA investigational device exemption (IDE) to study its Topaz heart valve replacement system.
Encouraging 12-month pilot clinical study results will be presented by Key Opinion Leader Dr. Lowell Kabnick at the prestigious Charing Cross Vascular Symposium in London on Tuesday, April 21st, 2026.
Stereotaxis (NYSE:STXS) announced today that it received FDA 510(k) clearance for its Synchrony system.
With approval to study the transcatheter replacement device in patients with severe tricuspid regurgitation, VDyne is advancing a treatment to compete with Edwards Lifesciences’ Evoque system.
Vantage’s intuitive three-step workflow, locate, dilate, decompress, enables physicians to perform procedures with consistency.
RALEIGH, N.C., April 2, 2026 /PRNewswire/ — Zeto, Inc., a medical technology company dedicated to making brain health insights through EEG a foundational vital sign in healthcare, announced that it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for Zeto New Wave™, its newest EEG system for outpatient clinics and homes.